NFAb-101 Repurposing Drug for Periodontal Surgery

NFAb-101 Repurposing Drug for Periodontal Surgery

Medical Wikipedia

Why periodontal requires new solution?

NFAb-101 is an old drug with Liposome coverd. Originally a commonly used antibiotic, it has been repackaged specifically for periodontal disease and dental plaque, and has been patented for a new indication. NFAb-101’s key function is to prevent plaque bacteria from forming a protective film (biofilm), making it difficult for bacterial growth, thereby reducing inflammation and the risk of recurrence.

Periodontal disease
(a common yet serious oral disease)

Approximately 50% of adults worldwide are affected by periodontal disease, and severe cases can lead to tooth loss, and worse vascular diseases.

High recurrence rate

Studies have shown that the recurrence rate for periodontal disease is 14% within one year after treatment.

Systemic risks

Periodontal disease is associated with conditions such as myocardial infarction, stroke, and diabetes, and has been shown to be a significant risk factor for overall health.

The Application

NFAb-101 is an innovative drug developed using a “repurposing” strategy.

Simply put, it was originally an antibiotic with long-standing medical use and proven safety. Through repositioning, the R&D team applied NFAb-101 to periodontal disease and dental plaque treatment, and obtained patents for this new indication.

The advantages of this strategy are

Lower development costs and time (the drug already has safety data)
Clearer regulatory pathways and faster time to market
High clinical acceptance (familiarity among physicians and patients)

Clinical applications of NFAb-101

Periodontal disease treatment – Assists with traditional teeth cleaning and surgery to reduce recurrence rates
Peri-implantitis – Prevents bone resorption and failure after dental implants
Postoperative infection control – Reduces bacterial infection after tooth extraction or periodontal surgery

NFAb-101’s mechanism of action

Inhibits biofilm formation in dental plaque
Reduces bacterial adhesion at the tooth-gum interface

Reduces periodontal inflammation and protects alveolar bone and gingival tissue.
Simply put, NFAb-101 blocks the “protective shield” of dental plaque, making it difficult for bacteria to survive and reproduce, thereby fundamentally reducing the risk of periodontal disease.

KKM’s research

Cell and animal studies have been completed, confirming efficacy and safety.
IND (Investigational Testing Application) is expected to be initiated in 2026.
Developed in collaboration with National Sun Yat-sen University, and Mackay Memorial Hospital, and other institutions, the product has been validated through clinical pathways within Taiwan’s dental community.

“NFAb-101 Repurposing Drug provides complete treatment for periodonal”